We are live on ! Find out more
NVO

Novo Nordisk

1,398 hedge funds and large institutions have $16.7B invested in Novo Nordisk in 2025 Q3 according to their latest regulatory filings, with 160 funds opening new positions, 506 increasing their positions, 549 reducing their positions, and 223 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.22% less ownership

Funds ownership: 9.09%8.88% (-0.22%)

8% less repeat investments, than reductions

Existing positions increased: 506 | Existing positions reduced: 549

6% less funds holding

Funds holding: 1,4821,398 (-84)

21% less capital invested

Capital invested by funds: $21.3B → $16.7B (-$4.57B)

28% less first-time investments, than exits

New positions opened: 160 | Existing positions closed: 223

32% less call options, than puts

Call options by funds: $2.04B | Put options by funds: $2.99B

32% less funds holding in top 10

Funds holding in top 10: 2517 (-8)

Holders
1,398
Holders Change
-84
Holders Change %
-5.67%
% of All Funds
18.3%
Holding in Top 10
17
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-32%
% of All Funds
0.22%
New
160
Increased
506
Reduced
549
Closed
223
Calls
$2.04B
Puts
$2.99B
Net Calls
-$946M
Net Calls Change
-$454M

NVO Hedge Fund Activity: Q3 2025 in Review

1,398 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q3 2025, worth a combined $16.7B — down 21% from $21.3B a quarter earlier.

Sellers outnumbered buyers: 223 funds closed out of NVO and 160 opened new positions — a net loss of 63 holders — while 549 trimmed existing stakes and 506 added.

The largest buyer was Franklin Resources, adding an estimated $800M. The largest seller was Jennison Associates, cutting an estimated $1.03B.

  • 1,398 institutional investors held Novo Nordisk (NVO) as of Q3 2025, down from 1,482 in Q2 2025.
  • Funds reported $16.7B of Novo Nordisk stock for Q3 2025, down 21% quarter-over-quarter.
  • 160 funds opened new Novo Nordisk positions in Q3 2025 and 223 closed out, a net change of -63 holders.
  • The largest Novo Nordisk buyer in Q3 2025 was Franklin Resources, an estimated $800M added.
  • The largest Novo Nordisk seller in Q3 2025 was Jennison Associates, an estimated $1.03B sold.

Based on aggregated 13F filings for Q3 2025.